X4 Pharmaceuticals, Inc Cash Flow Statement
XFOR|6 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$97M
FY2025
Free Cash Flow
-$97M
FY2025
Capital Expenditures
$60,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
X4 Pharmaceuticals, Inc used $97M in operating cash flow and negative free cash flow of $97M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- High leverage: Debt-to-equity ratio of 3.39
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|
| Net Income | -$101.2M | -$93.9M | -$62.1M | -$52.8M | -$33.3M | -$23.0M |
| Depreciation & Amortization | $419.0K | $513.0K | $351.0K | $103.0K | $103.0K | $285.0K |
| Operating Cash Flow | -$96.5M | -$77.1M | -$58.8M | -$48.1M | -$25.4M | -$21.6M |
| Capital Expenditures | $60.0K | $103.0K | $1.4M | $174.0K | $0 | $73.0K |
| Free Cash Flow | -$96.6M | -$77.2M | -$60.2M | -$48.2M | -$25.4M | -$21.7M |
| Share Buybacks | - | - | $0 | $0 | - | - |
| FCF Margin | - | - | -2006.0% | - | - | -620.3% |